Candel Therapeutics (CADL) Interest Coverage Ratio (2022 - 2025)
Candel Therapeutics' (CADL) quarterly Interest Coverage Ratio came in at 11.12 in Q4 2025, up 46.71% year-on-year from 7.58 in Q4 2024, and up 86.44% quarter-over-quarter from 82.03 in Q3 2025.
Candel Therapeutics (CADL) Interest Coverage Ratio (2022 - 2025) Analysis & Trends
Candel Therapeutics has disclosed Interest Coverage Ratio across 4 years of filings, most recently posting 11.12 for Q4 2025.
- Interest Coverage Ratio for Q4 2025 came in at 11.12, up 46.71% year-over-year; the trailing twelve-month figure through Dec 2025 was 22.78 (down 42.66% YoY), and the FY2025 annual result was 22.78, down 42.66% from the prior year.
- Interest Coverage Ratio came in at 11.12 for Q4 2025 at Candel Therapeutics, up from 82.03 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 11.12 in Q4 2025 to a low of 82.03 in Q3 2025.
- The 4-year median for Interest Coverage Ratio is 15.82 (2023), against an average of 22.92.
- Peak annual rise in Interest Coverage Ratio reached 46.71% in 2025, while the deepest fall reached 356.2% in 2025.
- Candel Therapeutics' Interest Coverage Ratio stood at 14.02 in 2022, then decreased by 9.39% to 15.33 in 2023, then plunged by 36.15% to 20.87 in 2024, then soared by 46.71% to 11.12 in 2025.
- The last three Interest Coverage Ratio figures came in at 11.12 (Q4 2025), 82.03 (Q3 2025), and 47.36 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Candel Therapeutics | 440.62 Mn | 440.62 Mn | - | -11.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.12 |
| Sep 30, 2025 | -82.03 |
| Jun 30, 2025 | -47.36 |
| Mar 31, 2025 | -26.57 |
| Dec 31, 2024 | -20.87 |
| Sep 30, 2024 | -17.98 |
| Jun 30, 2024 | -15.12 |
| Mar 31, 2024 | -12.23 |
| Dec 31, 2023 | -15.33 |
| Sep 30, 2023 | -13.25 |
| Jun 30, 2023 | -14.87 |
| Mar 31, 2023 | -15.82 |
| Dec 31, 2022 | -14.02 |
| Sep 30, 2022 | -17.11 |
| Jun 30, 2022 | -20.12 |